Houston, TX, United States of America

Yuqiang Wang

This inventor holds 1 USPTO granted patent. Top assignee: The University of Texas System. Active years: 1989.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuqiang Wang. Retrieved from https://idiyas.com/inventor/yuqiang-wang-f1cfubyo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 1989

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yuqiang Wang: Innovator in Aldophosphamide Compounds

Introduction

Yuqiang Wang is a notable inventor based in Houston, Texas. He has made significant contributions to the field of chemistry, particularly in the development of aldophosphamide compounds. His work focuses on innovative solutions for eliminating leukemic clonogenic cells from bone marrow.

Latest Patents

Yuqiang Wang holds a patent for a compound known as aldophosphamides. This compound features a specific structure where R can be CH₃ or C₂H₅, and R¹ can be various amine derivatives. The patent describes the use of these compounds to effectively eliminate occult leukemic clonogenic cells from bone marrow. Additionally, the compounds can target tumor cells in a host or organ, showcasing their potential in cancer treatment.

Career Highlights

Wang is affiliated with the University of Texas System, where he continues to engage in research and development. His innovative approach to chemistry has led to advancements that may significantly impact medical treatments.

Collaborations

Yuqiang Wang collaborates with David Farquhar, contributing to the advancement of their research initiatives.

Conclusion

Yuqiang Wang's work in the field of aldophosphamide compounds represents a significant advancement in medical chemistry. His innovative contributions have the potential to improve treatment options for leukemia and other cancers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…